Evidence map›Paper›PMID 29908077›Full record

ArticleAnnals of neurology2018

Genome sequencing uncovers phenocopies in primary progressive multiple sclerosis.

Xiaoming Jia, Lohith Madireddy, Stacy Caillier, Adam Santaniello, Federica Esposito, Giancarlo Comi, Olaf Stuve, Yuan Zhou, Bruce Taylor, Trevor Kilpatrick and 5 more

Open access · hybridAbstract read
In one paragraph

Article in Annals of neurology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. A disease-specific convergence of host and Epstein-Barr virus genetics in multiple sclerosis.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. The Impact of Multiple Sclerosis Disease Status and Subtype on Hematological Profile.International journal of environmental research and public health · 2021
    Article
  17. Review
  18. Endogenous Retroviruses in Nervous System Disorders.Pharmaceuticals (Basel, Switzerland) · 2021
    Review
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 4 countries.

Xiaoming JiaUCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA.
Lohith MadireddyUCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA.
Stacy CaillierUCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA.
Adam SantanielloUCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA.
Federica EspositoLaboratory of Human Genetics of Neurological Disorders, Institute of Experimental Neurology (INSpe), Division of Neuroscience, San Raffaele Scientific Institute, Milan, Italy.ORCID 0000-0003-2550-0805
Giancarlo ComiLaboratory of Human Genetics of Neurological Disorders, Institute of Experimental Neurology (INSpe), Division of Neuroscience, San Raffaele Scientific Institute, Milan, Italy.
Olaf StuveDepartment of Neurology and Neurotherapeutics, University of Texas Southwestern Medical, Dallas, TX.
Yuan ZhouMenzies Institute for Medical Research, University of Tasmania, Hobart, TAS, Australia.ORCID 0000-0003-1962-2574
Bruce TaylorMenzies Institute for Medical Research, University of Tasmania, Hobart, TAS, Australia.
Trevor KilpatrickDepartment of Anatomy and Neuroscience, The University of Melbourne, Parkville, VIC, Australia.
Filippo Martinelli-BoneschiLaboratory of Genomics of Neurological Diseases and Department of Neurology, Policlinico San Donato Hospital and Scientific Institute, San Donato Milanese, Italy.
Bruce A C CreeUCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA.
Jorge R OksenbergUCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA.
Stephen L HauserUCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA.
Sergio E BaranziniUCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA.
University of California, San Francisco · USSan Raffaele University of Rome · ITUniversity of Tasmania · AUThe University of Melbourne · AUThe University of Texas Southwestern Medical Center · USUniversity of Milan · IT

Funding

A Haplotype Map for Multiple SclerosisR01NS049477 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HAUSER, STEPHEN L · 2005 to 2014
$15.3M
GENE LINKAGE STUDY OF MULTIPLE SCLEROSIS SIBLING PAIRSR01NS026799 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HAUSER, STEPHEN L, OKSENBERG, JORGE R. · 1989 to 2018
$6.8M
Post GWAS approach to identify cell-specific genetic pathways underlying MS riskR01NS088155 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BARANZINI, SERGIO E · 2014 to 2018
$2.2M
The genetic basis of progression in multiple sclerosisR01NS099240 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BARANZINI, SERGIO E, SAWCER, STEPHEN JAMES · 2017 to 2021
$1.9M
NINDS NIH HHS R01 NS026799NINDS NIH HHS R01 NS049477NINDS NIH HHS R01 NS088155NINDS NIH HHS R01 NS099240
6 · The paper itself

Abstract

objectivePrimary progressive multiple sclerosis (PPMS) causes accumulation of neurological disability from disease onset without clinical attacks typical of relapsing multiple sclerosis (RMS). However, whether genetic variation influences the disease course remains unclear. We aimed to determine whether mutations causative of neurological disorders that share features with multiple sclerosis (MS) contribute to risk for developing PPMS.

methodsWe examined whole-genome sequencing (WGS) data from 38 PPMS and 81 healthy subjects of European ancestry. We selected pathogenic variants exclusively found in PPMS patients that cause monogenic neurological disorders and performed two rounds of replication genotyping in 746 PPMS, 3,049 RMS, and 1,000 healthy subjects. To refine our findings, we examined the burden of rare, potentially pathogenic mutations in 41 genes that cause hereditary spastic paraplegias (HSPs) in PPMS (n = 314), secondary progressive multiple sclerosis (SPMS; n = 587), RMS (n = 2,248), and healthy subjects (n = 987) genotyped using the MS replication chip.

resultsWGS and replication studies identified three pathogenic variants in PPMS patients that cause neurological disorders sharing features with MS: KIF5A p.Ala361Val in spastic paraplegia 10; MLC1 p.Pro92Ser in megalencephalic leukodystrophy with subcortical cysts, and REEP1 c.606 + 43G>T in Spastic Paraplegia 31. Moreover, we detected a significant enrichment of HSP-related mutations in PPMS patients compared to controls (risk ratio [RR] = 1.95; 95% confidence interval [CI], 1.27-2.98; p = 0.002), as well as in SPMS patients compared to controls (RR = 1.57; 95% CI, 1.18-2.10; p = 0.002). Importantly, this enrichment was not detected in RMS.

interpretationThis study provides evidence to support the hypothesis that rare Mendelian genetic variants contribute to the risk for developing progressive forms of MS. Ann Neurol 2018;83:51-63.

Indexed as

Genome-Wide Association StudyAdolescentAdultAgedChildChild, PreschoolCohort StudiesCystsFemaleGenotypeHereditary Central Nervous System Demyelinating DiseasesHumansKinesinsMaleMembrane ProteinsMembrane Transport ProteinsKIF5A protein, humanKinesinsMembrane ProteinsMembrane Transport ProteinsMLC1 protein, humanREEP1 protein, human

Identifiers

PMID29908077
PMCPMC6119489
OpenAlexW2808094593

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.